HK1248725A1 - 人抗-vegfr-2/kdr抗體 - Google Patents

人抗-vegfr-2/kdr抗體

Info

Publication number
HK1248725A1
HK1248725A1 HK18108387.4A HK18108387A HK1248725A1 HK 1248725 A1 HK1248725 A1 HK 1248725A1 HK 18108387 A HK18108387 A HK 18108387A HK 1248725 A1 HK1248725 A1 HK 1248725A1
Authority
HK
Hong Kong
Prior art keywords
vegfr
human anti
kdr antibodies
kdr
antibodies
Prior art date
Application number
HK18108387.4A
Other languages
English (en)
Inventor
Dan Lu
Zhenping Zhu
Original Assignee
Kadmon Corp Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc
Publication of HK1248725A1 publication Critical patent/HK1248725A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18108387.4A 2014-10-07 2018-06-29 人抗-vegfr-2/kdr抗體 HK1248725A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462061097P 2014-10-07 2014-10-07
PCT/US2015/054569 WO2016057726A2 (en) 2014-10-07 2015-10-07 Human anti-vegfr-2/kdr antibodies

Publications (1)

Publication Number Publication Date
HK1248725A1 true HK1248725A1 (zh) 2018-10-19

Family

ID=55653945

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108387.4A HK1248725A1 (zh) 2014-10-07 2018-06-29 人抗-vegfr-2/kdr抗體

Country Status (8)

Country Link
US (3) US10588968B2 (zh)
EP (1) EP3204423A4 (zh)
JP (1) JP2017531434A (zh)
CN (1) CN107531785B (zh)
CA (1) CA2995344C (zh)
EA (1) EA036257B1 (zh)
HK (1) HK1248725A1 (zh)
WO (1) WO2016057726A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3770172A4 (en) * 2018-03-19 2022-08-31 Pharmabcine Inc. ANTI-VEGFR-2 ANTIBODIES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
SI1487856T1 (sl) 2002-03-04 2010-12-31 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr (receptor z domeno kinaznega vkljuäśka) in njihove uporabe
JP2003310276A (ja) * 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd １２１４位チロシンがリン酸化したＫＤＲ／Ｆｌｋ−１に対する情報伝達分子の結合を阻害する物質およびその利用方法
CN101643509B (zh) * 2009-04-22 2011-09-07 南京医科大学 具人鼠交叉反应的抗vegfr-2单克隆抗体及其制备、应用
US20120316071A1 (en) * 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
CA2778953C (en) * 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
WO2012004631A2 (en) 2010-07-07 2012-01-12 Tubitak Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
US9441042B2 (en) * 2011-11-02 2016-09-13 Apexigen, Inc. Anti-KDR antibodies and methods of use
WO2013149219A2 (en) * 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US20150238601A1 (en) 2012-10-05 2015-08-27 Kadmon Corporation, Llc Treatment of ocular disorders
CA2926478C (en) * 2012-10-05 2022-05-24 Kadmon Corporation, Llc Rho kinase inhibitors
EA032679B1 (ru) * 2012-10-05 2019-07-31 Кадмон Корпорейшн, Ллк Человеческие анти-vegfr-2/kdr-антитела
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂

Also Published As

Publication number Publication date
US20200246456A1 (en) 2020-08-06
EP3204423A2 (en) 2017-08-16
CN107531785B (zh) 2021-06-29
US20230338524A1 (en) 2023-10-26
US11633475B2 (en) 2023-04-25
US20180250392A1 (en) 2018-09-06
EP3204423A4 (en) 2018-03-28
EA036257B1 (ru) 2020-10-20
WO2016057726A3 (en) 2016-09-01
JP2017531434A (ja) 2017-10-26
US10588968B2 (en) 2020-03-17
EA201790790A1 (ru) 2017-08-31
CN107531785A (zh) 2018-01-02
CA2995344C (en) 2021-05-04
WO2016057726A2 (en) 2016-04-14
CA2995344A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
IL250672A0 (en) Treatment regimens using anti-nkg2a antibodies
IL246661B (en) Human antibodies to pd–l1
SG11201608616VA (en) Patient interfaces
IL247072A0 (en) Medical use
HUE051354T2 (hu) Terapeutikum
AU358462S (en) Patient interface
SG11201703928QA (en) Patient interface
PL3193995T3 (pl) Interfejs do współpracowania z pacjentem
IL273265A (en) New combinations for antigen-based therapy
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201509130D0 (en) Medical balloon
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
GB201413357D0 (en) Antibodies for treatment and diagnosis
IL250017A0 (en) Eye examination devices
SG11201608284XA (en) Medical imaging
SG10201404895XA (en) Diagnosis
HK1248725A1 (zh) 人抗-vegfr-2/kdr抗體
GB201401806D0 (en) Novel methods for diagnosis and therapy
ZA201608886B (en) Human cytolytic fusion proteins
AU354622S (en) Patient interface
GB201414371D0 (en) Protein modification